J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burgos-Vargas, R.
Right arrow Articles by Tuerck, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burgos-Vargas, R.
Right arrow Articles by Tuerck, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

PEDIATRICS

Pharmacokinetics of Meloxicam in Patients With Juvenile Rheumatoid Arthritis

Rubén Burgos-Vargas, MD, Ivan Foeldvari, MD, Angelika Thon, MD, Ronald Linke, MD and Dietrich Tuerck, PhD

From the Department of Rheumatology, Hospital General de Mexico, Mexico (Dr. Burgos-Vargas); the Pediatric Rheumatology Clinic, Allgemeines Krankenhaus Eilbek, Hamburg, Germany (Dr. Foeldvari); the Department of Pediatric Rheumatology, University Children Hospital, Hannover, Germany (Dr. Thon); and the Department of Clinical Research, Boehringer Ingelheim Pharma KG (Dr. Linke) and the Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma KG, Biberach, Germany (Dr. Tuerck).

The pharmacokinetics of a meloxicam suspension were studied in 18 children with juvenile rheumatoid arthritis. Children received a single 0.25-mg/kg dose up to a maximum of 15 mg. Pharmacokinetic parameters after the first dose were calculated by noncompartmental methods. Geometric mean (percent coefficient of variation for geometric mean [gCV]) Cmax, AUC0-{infty}, apparent clearance, apparent volume of distribution, and elimination half-life values were 1.24 µg/mL (47% gCV), 25.6 µg•h/mL (81% gCV), 0.17 mL/min/kg (83% gCV), 0.19 L/kg (63% gCV), and 13.4 hours (54% gCV) in the younger group and 1.89 µg/mL (25% gCV), 35.8 µg•h/mL (21% gCV), 0.12 mL/min/kg (23% gCV), 0.13 L/kg (22% gCV), and 12.7 hours (21% gCV) for the older group, respectively. Area under the curve, volume of distribution, and clearance tended to be higher in the younger group, whereas elimination half-lives were similar. A post hoc comparison to pharmacokinetic data in adults revealed no relevant differences. Thus, a common body weight-normalized dose is considered appropriate for children older than 2 years.

Key Words: Meloxicam • pediatrics • pharmacokinetics • juvenile rheumatoid arthritis (JRA)

Address for reprints: Dr. Dietrich Tuerck, Boehringer Ingelheim Pharma KG, Department of Drug Metabolism and Pharmacokinetics, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American College of Clinical Pharmacology